11 January 2022 ORYZON announces new Senior VP of Clinical Development and Global Medical Affairs, continuing its expansion of US corporate activities
4 January 2022 ORYZON announces approval for Serbian arm of PORTICO, vafidemstat’s Phase IIb trial in Borderline Personality Disorder
13 December 2021 ORYZON at ASH-2021: iadademstat 36-month ALICE data demonstrate robust efficacy in combination with azacitidine in AML
22 November 2021 ORYZON announces new Global Chief Business Officer and expansion of US corporate activities
17 November 2021 ORYZON enrolls first patient in EVOLUTION, a Phase IIb clinical trial with vafidemstat in schizophrenia
15 November 2021 ORYZON publishes paper in ACS Pharmacology & Translational Science supporting best-in-class performance of iadademstat in Oncology
9 November 2021 ORYZON to present new clinical data and corporate updates at international conferences in November and December